Gilead Sciences: Triple Negative Breast Neoplasms trials

The registry lists 11 Triple Negative Breast Neoplasms studies with Gilead Sciences as lead sponsor. 2 are open to participants now and 3 have results posted.

Phase 1 4Phase 2 6Phase 3 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast CancerRecruitingNCT06926920Phase 1/2
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)RecruitingNCT05633654Phase 3
• Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast CancerTerminatedNCT04958785Phase 2Results posted
• Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)CompletedNCT02574455Phase 3Results posted
• Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial CancerCompletedNCT01631552Phase 1/2Results posted
• Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast CancerActive, not recruitingNCT05382299Phase 3
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast CancerActive, not recruitingNCT05382286Phase 3
• Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid TumorsActive, not recruitingNCT05101096Phase 1/2
• Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior TreatmentsActive, not recruitingNCT04454437Phase 2
• A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced CancersTerminatedNCT04025216Phase 1
• Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast CancerWithdrawnNCT02161679Phase 2